M&A Deal Summary |
|
|---|---|
| Date | 2013-09-04 |
| Target | Rochester Medical |
| Sector | Medical Products |
| Buyer(s) | C. R. Bard |
| Deal Type | Add-on Acquisition |
| Deal Value | 262M USD |
| Advisor(s) | Piper Sandler & Co. (Financial) Dorsey & Whitney (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1907 |
| Sector | Medical Products |
| Employees | 14,900 |
| Revenue | 3.7B USD (2016) |
C. R. Bard, Inc. is a multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology, and surgical specialties. C. R. Bard was formed in 1907 and is based in Murray Hill, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 21 of 23 |
| Sector: Medical Products M&A | 17 of 18 |
| Type: Add-on Acquisition M&A Deals | 20 of 22 |
| State: Minnesota M&A | 3 of 3 |
| Country: United States M&A | 20 of 22 |
| Year: 2013 M&A | 2 of 3 |
| Size (of disclosed) | 1 of 14 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-08-19 |
Medafor
Minneapolis, Minnesota, United States Medafor, Inc., is a developer and supplier of plant based hemostatic agents. Medafor develop and market its unique, patented hemostatic technology based on engineered biopolymeric microporous particles. |
Buy | $200M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-10-23 |
NeoMend
Irvine, California, United States NeoMend, Inc., is a developer and supplier of sprayable surgical sealants and anti-adhesion products. An innovator in sealant and adhesion-prevention products for the surgical marketplace focused on the design, development and commercialization of innovative surgical sealants and adhesion prevention products derived from the Progel® technology platform. |
Buy | $140M |